GROW is expanding its European footprint with Nimbus Health – launching its first branded medical cannabis extracts.
Fully licensed pharmaceutical wholesaler and manufacturer from Germany, Nimbus, has received its first orders from pharmacies. This signals that the first German patients have received a prescription for the GROW branded extract.
The launch marks GROW’s engagement in the largest medical cannabis market in Europe, and the only market worldwide with reimbursement for an estimated 60 per cent or more of patients who apply for special approval with their insurance companies.
CEO of GROW, Ben Langley, stated: “We’re thrilled that patients in Germany, Europe’s largest legal medical cannabis market, are now benefiting from GROW branded cannabis medicines.
“At GROW, we understand the unmet need faced by many patients living with chronic pain and palliative conditions. This licensing agreement with Nimbus is a further positive step towards our purpose of bringing new and innovative solutions to physicians and their patients.
Read more: Grow group – innovating cannabis medicines and improving access
“We seek to make these products more affordable and more accessible within the healthcare systems of all countries where GROW operates.”
CEO of Nimbus Health, Linus Weber, added: “At Nimbus Health, we’re excited about our collaboration with GROW, with the short-term goal of offering a broad range of GROW trademark extracts, including various THC CBD formulations, as well as unique strains of medical cannabis flower, ranging from lower to higher THC strains, THC CBD balanced strains and later CBD dominant strains.”
The medical cannabis extract product has the cannabinoid ratio THC10:CBD15 and offers an oral, non-inhalative prescription option for physicians with patients who could benefit from a combination of these two cannabinoids.
The company highlights that, as CBD is not intoxicating or psychoactive, products with a higher ratio of CBD are an option physicians consider with patients who are sensitive to the effects of THC.
Publications, insurance companies and medical experts report that physicians in Germany prescribe medical cannabis products with THC and CBD to manage symptoms such as chronic pain, spasticity, anorexia/wasting and chemo-induced nausea, as well as symptoms of neurological and psychological disorders.
To cater to the wide variety of patient needs, GROW is partnering with leading medical cannabis companies and developing the cannabis medicines and technologies of the future via biotechnological research and development.
[activecampaign form=31]
